Scher HI - Search Results

1

Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy.

Autio KA, Antonarakis ES, Mayer TM, Shevrin DH, Stein MN, Vaishampayan UN, Morris MJ, Slovin SF, Heath EI, Tagawa ST, Rathkopf DE, Milowsky MI, Harrison MR, Beer TM, Balar AV, Armstrong AJ, George DJ, Paller CJ, Apollo A, Danila DC, Graff JN, Nordquist L, Dayan Cohn ES, Tse K, Schreiber NA, Heller G, Scher HI. Autio KA, et al. Among authors: scher hi. Eur Urol Open Sci. 2021 Nov 17;34:70-78. doi: 10.1016/j.euros.2021.09.015. eCollection 2021 Dec. Eur Urol Open Sci. 2021. PMID: 34934969 Free PMC article.

2

Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer.

Seidman AD, Scher HI, Petrylak D, Dershaw DD, Curley T. Seidman AD, et al. Among authors: scher hi. J Urol. 1992 Mar;147(3 Pt 2):931-4. doi: 10.1016/s0022-5347(17)37426-8. J Urol. 1992. PMID: 1371564 Clinical Trial.

3

Post-therapy change in prostate-specific antigen levels as a clinical trial endpoint in hormone-refractory prostatic cancer: a trial with 10-ethyl-deaza-aminopterin.

Schultz PK, Kelly WK, Begg C, Liebertz C, Cohen L, Scher HI. Schultz PK, et al. Among authors: scher hi. Urology. 1994 Aug;44(2):237-42. doi: 10.1016/s0090-4295(94)80138-x. Urology. 1994. PMID: 7519382 Free article. Clinical Trial.

4

Acid phosphatase: defining a role in androgen-independent prostate cancer.

Steineck G, Kelly WK, Mazumdar M, Vlamis V, Schwartz M, Scher HI. Steineck G, et al. Among authors: scher hi. Urology. 1996 May;47(5):719-26. doi: 10.1016/s0090-4295(96)00017-9. Urology. 1996. PMID: 8650872

5

Clinical use of posttherapy prostate-specific antigen changes in advanced prostate cancer.

Kelly WK, Slovin S, Scher HI. Kelly WK, et al. Among authors: scher hi. Semin Oncol. 1996 Dec;23(6 Suppl 14):8-14. Semin Oncol. 1996. PMID: 8996578 Review.

6

Targeted therapy for prostate cancer: the Memorial Sloan-Kettering Cancer Center approach.

Slovin SF, Livingston PO, Rosen N, Sepp-Lorenzino L, Kelly WK, Mendelsohn J, Scher HI. Slovin SF, et al. Among authors: scher hi. Semin Oncol. 1996 Dec;23(6 Suppl 14):41-8. Semin Oncol. 1996. PMID: 8996585 Review.

7

Steroid hormone withdrawal syndromes. Pathophysiology and clinical significance.

Kelly WK, Slovin S, Scher HI. Kelly WK, et al. Among authors: scher hi. Urol Clin North Am. 1997 May;24(2):421-31. doi: 10.1016/s0094-0143(05)70389-x. Urol Clin North Am. 1997. PMID: 9126240

8

Immunological approaches for the treatment of prostate cancer.

Slovin SF, Kelly WK, Scher HI. Slovin SF, et al. Among authors: scher hi. Semin Urol Oncol. 1998 Feb;16(1):53-9. Semin Urol Oncol. 1998. PMID: 9508084 Review.

9

Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers.

Zhang S, Zhang HS, Reuter VE, Slovin SF, Scher HI, Livingston PO. Zhang S, et al. Among authors: scher hi. Clin Cancer Res. 1998 Feb;4(2):295-302. Clin Cancer Res. 1998. PMID: 9516914

10

Interferon-gamma and monoclonal antibody 131I-labeled CC49: outcomes in patients with androgen-independent prostate cancer.

Slovin SF, Scher HI, Divgi CR, Reuter V, Sgouros G, Moore M, Weingard K, Pettengall R, Imbriaco M, El-Shirbiny A, Finn R, Bronstein J, Brett C, Milenic D, Dnistrian A, Shapiro L, Schlom J, Larson SM. Slovin SF, et al. Among authors: scher hi. Clin Cancer Res. 1998 Mar;4(3):643-51. Clin Cancer Res. 1998. PMID: 9533532

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

698 results

Search Page

Filters